Lung CancerNCT06514248
Clinical Evaluation of the V5-LU01 AI Software in Thoracic CT for V5med Inc.
A study testing V5med Lung AI in people with Lung Cancer, run by V5med Inc. at 1 site in United States.
Trial summary
STUDY DESIGN: This is a two-arm retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that radiologist's performance aided with V5med Lung AI is superior to the unaided for detecting qualified lung nodules. Read more about this study
- Who is it for?
- Ages 55 to 77 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- V5med Lung AI
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Dec 2023to 17 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 77 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Screening chest CT taken of asymptomatic patients age 55 - 77 with history of smoking
- Non-screening chest CT of an adult (age 18 and older) without comorbidity
- Primary Lung Cancer, Biopsy-proven with radiology report
- <= 2.5mm slice spacing, no gaps
- Standard reconstruction kernels
- Maximum of 7 lung nodules per CT scan
- Nodules must be 4-30mm in size (though majority of them will be 20mm or smaller)
Who cannot join
- Acute pneumothorax
- Incomplete inclusion of both lungs, within the field of view, including both Apices
- Excessive motion artifacts or beam-hardening artifacts
- Symptomatic patients with co-morbidities
Trial locations and contacts
1 site in 1 country.
United States1 site
Arlington Innovation Center: Health Research
Arlington, Virginia, 22203
About this study
Official title: Evaluation of V5 Lung AI Software With A Two-Arm Comparative Reader Study
STUDY DESIGN:
This is a two-arm retrospective, multi-reader, multi-case, (MRMC) randomized reader study.
Read more
OBJECTIVE:
Primary: The primary objective of this clinical study is to prove that radiologist's performance aided with V5med Lung AI is superior to the unaided for detecting qualified lung nodules.
Secondary: The secondary objective of this clinical study is to prove that the radiologist's reading time is not significantly increased when aided with V5med Lung AI.
Addition Objectives: To prove that the agreement (e.g., in kappa correlation coefficient) between experts and radiologist's Lung-RADS score aided with V5med Lung AI is superior to the unaided.
NUMBER OF SUBJECTS:
Retrospective CT studies from approximately 350 patients will be included in the study with approximately 170 true positive cases and 180 normal cases.
PRIMARY ENDPOINTS:
Scores given by the radiologists with and without V5med Lung AI will be recorded and compared to the true status of the study-cases. The frequency of the scores for each method (Aided, Unaided) will be tabulated and LROC curves constructed along with sensitivity, specificity, PPV, NPV and clinical actions. Additionally, machine nodule detection rate and false positives per patient on normal cases will be measured.
PATIENT POPULATION:
The study will target approximately two hundred (200) patients whose CT lung nodules were shown to be cancer and one hundred and eighty (150) patients who have no lung nodule greater than 4mm. The patient population will be consistent with the national lung cancer screening protocols.
Read the detailed description
Overview of the Study:
A reader study with sixteen participating radiologists will be conducted. A location-specific receiver operating characteristic (LROC) curve will be used to evaluate radiologists' detection performance in detecting qualified lung nodules on chest CT scans with and without the use of the V5med Lung AI system. The reading time for each case will also be recorded.
The 16 study radiologists will be split into two groups, X and Y. The 350 chest CT scans will be split into two subsets, A and B. Group X radiologists will interpret subset A without AI and subset B with V5med Lung AI. Group Y radiologist will interpret subset B without AI and subset A with AI. After a minimum of one month, each radiologist group will interpret the same images again but in the reverse order with regard to study modes (without AI and with AI). Please see Figures 1 and 2 for detailed arrangement of the radiologist interpretation sessions.
During the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation.
During the second reading (i.e., aided reading) session, the radiologist will be presented with a chest CT with CADe marks displayed on the "left window" and the same chest CT without CADe marks displayed on the "right window". If the radiologist confirms a nodule, the radiologist will mark the location on the chest CT displayed on the right window. This may or may not correspond to the locations of the CADe marks as displayed on the left window. The same as in the baseline study, the radiologist will assign a score (level of suspicion) to each suspicious location and provide a Lung-RADS score for the chest CT case, if at least one location on the CT is marked.
Based on the suspicious locations and their scores (level of suspicion) assessed by study radiologists, LROC curves can be constructed for both the baseline and the aided reads, and the significance of any difference will be calculated. The LOS score will also be used to calculate sensitivity, specificity, PPV and NPV.
Number and types of Chest CT cases:
Retrospective chest CT image series from approximately 350 cases will be included in the study. Approximately two hundred (200) cases will have at least one nodule size greater than 4mm. These cases will have radiology-prove report and/or biopsy-confirmed cancers. Also included as nodule images are those where a nodule was not detected at that time, but was detected and acted on based on a subsequent CT. These are the prior images where the nodule can be identified in the same location as on the "current" image confirmed by the radiologist expert panel (using a majority of three as the decision criterion). In addition, approximately one hundred and fifty (150) cases will not have a nodule size greater than 4mm.
The selected chest CT cases for the 2-arm comparative reader study, randomly selected from a larger pool of CT cases, will be enriched in the following way:
- Lung nodules (cancers and benign nodules) will be nodule size ranging from 4mm to 30 mm. The proportion of nodules 20 mm or less may take majority of the cases with nodule(s) since this lung lesion size range is where we expect the major impact of this software to be.
- Non-Solid (ground glass) nodules will be added to the study dataset (based on availability) to determine the performance of the system on non-solid nodules. For this group, to have sufficient cases, we may include more benign (non-malignant) non-solid nodules.
- In this project, VIRGINIA TECH study team will perform a machine standalone test of the V5med Lung AI algorithm followed by a reader performance evaluation study. V5med Technologies will provide a system configured with the operating point set to be used for the reader studies and a configuration for an "open" system to be used for machine testing and to generate free-response ROC (FROC) curve.
The Design of Two-Arm Comparative Study:
The First Arm Study:
Perform a baseline reader study without any special tool. The reader is asked to mark all potential nodules not less than 4mm. For each mark, the size of region of interest (ROI), reader score (level of suspicion), and time spent will be recorded for the statistical analyses.
The Second Arm Study:
Perform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study.
The primary study hypothesis is that the detection of lung nodules with the use of V5med Lung AI and associated functions is superior to the detection of lung nodules without the use of V5med Lung AI, as measured by the area under the LROC curve.
- Conditions
- Lung Cancer
- Being tested
- V5med Lung AI
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
V5med Lung AIDevice
During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the "left window" and the same original without any AI mark with be display on the "right window". Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension.
| Study group | Role | What they receive |
|---|---|---|
| Reader Study without AI (Baseline ) | No intervention | During the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation. |
| Reader Study with AI (Aided by V5med Lung AI) | Active comparator | Perform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study. Receives: Device: V5med Lung AI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules
The detection rates in accuracy, sensitivity, and specificity on clinically actionable lung nodules were computed and compared for Aim 1 (baseline) and Arm 2 (study participants were aided with V5med Lung AI) studies.
Measured: 6 months
Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal
The areas under location-specific Receiver Operating Characteristic (LROC) curves were computed and compared for Aim 1 (baseline) and Aim 2 (study participants were aided with V5med Lung AI).
Measured: 6 months
Secondary outcomes (1)
Average Reading Time Per Case
The average reading times per reader per case were computed and comapred in both Aim 1 and Arm 2 (study participants were aided with ClearRead CT software) studies.
Measured: 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2024
- Study start18 Dec 2023
- Primary completion17 May 2024
- Study completion17 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- V5med Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06514248
- Sponsor's protocol ID
- 23-806
- Status last verified
- Jul 2024
- First submitted
- 5 Jul 2024
- Last updated
- 23 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of V5 Lung AI Software With A Two-Arm Comparative Reader Study
- ClinicalTrials.gov ID
- NCT06514248
- Acronym / sponsor ID
- 23-806
- Conditions
- Lung Cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- V5med Inc.Industry (pharma, biotech, devices)
- Study start
- 18 Dec 2023 (actual)
- Primary completion
- 17 May 2024 (actual)
- Study completion
- 17 May 2024 (actual)
- First posted
- 23 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
STUDY DESIGN:
This is a two-arm retrospective, multi-reader, multi-case, (MRMC) randomized reader study.
OBJECTIVE:
Primary: The primary objective of this clinical study is to prove that radiologist's performance aided with V5med Lung AI is superior to the unaided for detecting qualified lung nodules.
Secondary: The secondary objective of this clinical study is to prove that the radiologist's reading time is not significantly increased when aided with V5med Lung AI.
Addition Objectives: To prove that the agreement (e.g., in kappa correlation coefficient) between experts and radiologist's Lung-RADS score aided with V5med Lung AI is superior to the unaided.
NUMBER OF SUBJECTS:
Retrospective CT studies from approximately 350 patients will be included in the study with approximately 170 true positive cases and 180 normal cases.
PRIMARY ENDPOINTS:
Scores given by the radiologists with and without V5med Lung AI will be recorded and compared to the true status of the study-cases. The frequency of the scores for each method (Aided, Unaided) will be tabulated and LROC curves constructed along with sensitivity, specificity, PPV, NPV and clinical actions. Additionally, machine nodule detection rate and false positives per patient on normal cases will be measured.
PATIENT POPULATION:
The study will target approximately two hundred (200) patients whose CT lung nodules were shown to be cancer and one hundred and eighty (150) patients who have no lung nodule greater than 4mm. The patient population will be consistent with the national lung cancer screening protocols.
Detailed description
Overview of the Study:
A reader study with sixteen participating radiologists will be conducted. A location-specific receiver operating characteristic (LROC) curve will be used to evaluate radiologists' detection performance in detecting qualified lung nodules on chest CT scans with and without the use of the V5med Lung AI system. The reading time for each case will also be recorded.
The 16 study radiologists will be split into two groups, X and Y. The 350 chest CT scans will be split into two subsets, A and B. Group X radiologists will interpret subset A without AI and subset B with V5med Lung AI. Group Y radiologist will interpret subset B without AI and subset A with AI. After a minimum of one month, each radiologist group will interpret the same images again but in the reverse order with regard to study modes (without AI and with AI). Please see Figures 1 and 2 for detailed arrangement of the radiologist interpretation sessions.
During the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation.
During the second reading (i.e., aided reading) session, the radiologist will be presented with a chest CT with CADe marks displayed on the "left window" and the same chest CT without CADe marks displayed on the "right window". If the radiologist confirms a nodule, the radiologist will mark the location on the chest CT displayed on the right window. This may or may not correspond to the locations of the CADe marks as displayed on the left window. The same as in the baseline study, the radiologist will assign a score (level of suspicion) to each suspicious location and provide a Lung-RADS score for the chest CT case, if at least one location on the CT is marked.
Based on the suspicious locations and their scores (level of suspicion) assessed by study radiologists, LROC curves can be constructed for both the baseline and the aided reads, and the significance of any difference will be calculated. The LOS score will also be used to calculate sensitivity, specificity, PPV and NPV.
Number and types of Chest CT cases:
Retrospective chest CT image series from approximately 350 cases will be included in the study. Approximately two hundred (200) cases will have at least one nodule size greater than 4mm. These cases will have radiology-prove report and/or biopsy-confirmed cancers. Also included as nodule images are those where a nodule was not detected at that time, but was detected and acted on based on a subsequent CT. These are the prior images where the nodule can be identified in the same location as on the "current" image confirmed by the radiologist expert panel (using a majority of three as the decision criterion). In addition, approximately one hundred and fifty (150) cases will not have a nodule size greater than 4mm.
The selected chest CT cases for the 2-arm comparative reader study, randomly selected from a larger pool of CT cases, will be enriched in the following way:
- Lung nodules (cancers and benign nodules) will be nodule size ranging from 4mm to 30 mm. The proportion of nodules 20 mm or less may take majority of the cases with nodule(s) since this lung lesion size range is where we expect the major impact of this software to be.
- Non-Solid (ground glass) nodules will be added to the study dataset (based on availability) to determine the performance of the system on non-solid nodules. For this group, to have sufficient cases, we may include more benign (non-malignant) non-solid nodules.
- In this project, VIRGINIA TECH study team will perform a machine standalone test of the V5med Lung AI algorithm followed by a reader performance evaluation study. V5med Technologies will provide a system configured with the operating point set to be used for the reader studies and a configuration for an "open" system to be used for machine testing and to generate free-response ROC (FROC) curve.
The Design of Two-Arm Comparative Study:
The First Arm Study:
Perform a baseline reader study without any special tool. The reader is asked to mark all potential nodules not less than 4mm. For each mark, the size of region of interest (ROI), reader score (level of suspicion), and time spent will be recorded for the statistical analyses.
The Second Arm Study:
Perform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study.
The primary study hypothesis is that the detection of lung nodules with the use of V5med Lung AI and associated functions is superior to the detection of lung nodules without the use of V5med Lung AI, as measured by the area under the LROC curve.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Reader Study without AI (Baseline ) | No intervention | –During the baseline reading session the radiologist will mark each location of qualified nodules and assign a score. If at least one suspicious nodule is observed, the radiologist will also indicate a Lung-RADS score (i.e., 2, 3, 4A, 4B, or 4X) at the end of case interpretation. |
| Reader Study with AI (Aided by V5med Lung AI) | Active comparator | Device: V5med Lung AIPerform another reader study using the V5med Lung AI as the aided read. The reader is asked to mark all potential nodules not less than 4mm assisted by V5med Lung AI. Some or majority of ROIs' parameters will be pre-filled by V5med Lung AI. The reader will make final determination for each location. The marked location, LOS score, Lung-RADS score, and time spent will be recorded for the statistical analyses and compared to the first arm study. |
Who may qualify
- Ages
- 55 to 77 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Screening chest CT taken of asymptomatic patients age 55 - 77 with history of smoking
- Non-screening chest CT of an adult (age 18 and older) without comorbidity
- Primary Lung Cancer, Biopsy-proven with radiology report
- <= 2.5mm slice spacing, no gaps
- Standard reconstruction kernels
Key exclusion criteria (4 listed)
- Acute pneumothorax
- Incomplete inclusion of both lungs, within the field of view, including both Apices
- Excessive motion artifacts or beam-hardening artifacts
- Symptomatic patients with co-morbidities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| V5med Lung AIDuring the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed on the "left window" and the same original without any AI mark with be display on the "right window". Deeming a nodule, the radiologist will mark location. These may or may not correspond to the locations of the CADe markers. As in the baseline study, the radiologist will assign a level of suspicious to each mark and provide a Lung-RADS score and the size of longest dimension. | Device | Reader Study with AI (Aided by V5med Lung AI) |
Primary outcome
Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules
Time frame: 6 months
The detection rates in accuracy, sensitivity, and specificity on clinically actionable lung nodules were computed and compared for Aim 1 (baseline) and Arm 2 (study participants were aided with V5med Lung AI) studies.
Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal
Time frame: 6 months
The areas under location-specific Receiver Operating Characteristic (LROC) curves were computed and compared for Aim 1 (baseline) and Aim 2 (study participants were aided with V5med Lung AI).
1 secondary outcome
Average Reading Time Per Case
Time frame: 4 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2024.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing V5med Lung AI in people with Lung Cancer, run by V5med Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2024.